ClinicalTrials.Veeva

Menu

"Ultra" Enhanced Recovery After Surgery (E.R.A.S.) in Laparoscopic Colectomy for Cancer

A

AUSL Romagna Rimini

Status and phase

Completed
Phase 3

Conditions

Colonic Cancer

Treatments

Other: Classic E.R.A.S.
Other: "Ultra" E.R.A.S.

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Background. Enhanced Recovery After Surgery (E.R.A.S.) programs are now widely accepted in colonic laparoscopic resections because of faster recovery and less perioperative complications.

Objective. Aim of this study is to assess safety and feasibility of discharging patients operated on by laparoscopic colectomy on Post Operative Day 2 (POD 2), so long as the first flatus has passed and in the absence of complication-related symptoms.

Design & Settings. Non-inferiority, open-label, single center, prospective, randomized study comparing "Ultra" to Classic E.R.A.S. with discharge on POD 2 and 4 respectively.

Patients. 765 patients with resectable non metastatic colonic cancer were analyzed: 384 patients were assigned to "Ultra" E.R.A.S. and 381 to Classic E.R.A.S.

Main Outcome Measures. Demographics, clinico-pathological, ASA class and morbi-mortality, along with surgical complications, re-operation and readmission rate were recorded and compared. Primary end-point was mortality; secondary end-points were morbidity, re-admission and re-operation rate.

Limitations. It is a single center experience; it is not double-blind, with the intrinsic risk of intentional or unconscious bias; exclusion criteria because of "non compliance" may be considered arbitrary.

Full description

From January 2008 to September 2015, 765 patients were prospectively randomized for early discharge after laparoscopic colectomy according to E.R.A.S. programs: after obtained informed consent, 384 patients were randomly assigned to the "Ultra" E.R.A.S. group and 381 to Classic E.R.A.S. group.

Enrollment

765 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Resectable colonic cancer

Exclusion criteria

  • metastatic patients
  • T4b tumors
  • urgent operations (because of obstruction, perforation or bleeding refractory to conservative treatment)
  • huge neoplasms (>7cm)
  • positive cytology in peritoneal lavage or frank carcinosis
  • inability to tolerate pneumoperitoneum
  • ASA class 4
  • severe portal hypertension with hepato-caval gradient >10mmHg

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

765 participants in 2 patient groups

"Ultra" E.R.A.S.
Experimental group
Description:
Discharge patients on Post Operative Day 2
Treatment:
Other: "Ultra" E.R.A.S.
Classic E.R.A.S.
Active Comparator group
Description:
Discharge patients on Post Operative Day 4
Treatment:
Other: Classic E.R.A.S.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems